Back to List View Graph View

Immunotherapy

Immunotherapy is a broad class of therapeutic approaches that harness, enhance, or redirect the immune system to recognize and control disease.

Where the papers sit

46 papers from the last 6 months study immunotherapy directly · updated from PubMed 16 Nov 2026

  • Tumor Microenvironment Remodeling

    Tumor immunotherapy is shifting toward active remodeling of the microenvironment and construction of local immune-activation niches. Approaches include PI3Kγ-inhibitor liposomes, engineered tertiary lymphoid structures, B7H2-displaying bacteria, probiotics, and mRNA nanoparticles targeting tumor-associated macrophages. Regnase-1 editing in B7-H3-CAR T cells seeks to sustain cytotoxic activity, while neighboring cancer cells can suppress TLS function. The main open question is whether these engineered changes translate into durable antitumor responses across tumor types.

    10 papers · 21.7%

  • Mechanisms of Checkpoint Response

    Checkpoint response is being linked to tumor suppressive circuits, cancer metabolism, and CD8+ T-cell function rather than PD-1 status alone. Mutant p53 repression of SPP1, MerTK inhibition, LIM and SH3 protein 1 loss, and cofilin1-driven cytoskeletal remodeling emerge as mechanisms of sensitivity or resistance. Obesity, diet, and the microbiome complicate metabolic prediction, with obesity producing conflicting effects. Single-cell models and targeted combinations aim to overcome immunosuppression in solid and hematologic cancers.

    9 papers · 19.6%

  • Immunotherapy in Lung Cancer

    Immunotherapy is moving from treatment of advanced NSCLC toward biomarker-selected and perioperative use. ctDNA tumor fraction, KRAS G12C status, and PET-based assessment are being evaluated for regimen selection and prognosis. Adjuvant therapy after nodal downstaging and METTL14/Wnt9a/β-catenin inhibition support combination strategies, while long-term responders remain a key outcome group. Real-world studies increasingly weigh overall survival, treatment volume, and healthcare costs.

    7 papers · 15.2%

  • Others — Immunotherapy Response and Access

    Immune signatures, clinical response prediction, and patient experience recur across the cancer-focused work. Studies link polyamine, senescence, and multi-omic features to prognosis or immunotherapy selection, while others test combinations in breast cancer or assess radiomics in melanoma. Access, decision regret, and treatment choices are also examined. The non-cancer neurological and infectious-disease studies leave no single biological direction.

    16 papers · 34.8%

  • Others — Antigen-Targeted Immune Therapies

    Antigen-directed immune therapy spans engineered regulatory T cells, off-the-shelf CAR33 T cells, and antibody-based treatment. The studies target distinct problems, from α-synuclein-driven neuroinflammation to acute myeloid leukemia and parasite burden. One mathematical model addresses delayed responses in combined cancer therapy rather than a specific antigen product. Shared emphasis on experimental translation is stronger than any common disease or therapeutic direction.

    4 papers · 8.7%

PARADIGM SHIFT

Obesity and related metabolic states can enhance, rather than impair, cancer immunotherapy

The diet–microbiome study of cancer immunotherapy in obesity reported that diet-dependent gut-microbiome remodeling promotes antitumor immunity and may explain greater immune-checkpoint blockade efficacy in obesity 42838033Oct. The metabolic-predictor study of anti-PD-1 therapy in locally advanced or metastatic esophageal cancer likewise found that high BMI or metabolic syndrome was associated with superior survival, response rates, and favorable immune profiles 42711346Sep. Together, these findings reverse the expectation that obesity-related metabolic dysfunction is uniformly unfavorable for immunotherapy: obesity-associated host and microbial states may instead improve treatment responsiveness, making metabolic context a potential therapeutic variable rather than merely a risk factor.

Papers

The 46 papers from the last 6 months that study immunotherapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Tumor Microenvironment Remodeling (10)
  1. Engineering Subcutaneous Ectopic Tertiary Lymphoid Structures as Personalized Immune-Activation Niches for Cancer Immunotherapy. ACS applied bio materials · 20 Oct 2026 PMID 42900868
  2. Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science translational medicine · 16 Sept 2026 PMID 42748218
  3. Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
  4. Decondensing cancer immunotherapy. Science (New York, N.Y.) · 10 Sept 2026 PMID 42721256
  5. Surface display of co-stimulatory ligand B7H2 on engineered bacteria enhances tumor immunotherapy. Cell reports. Medicine · 3 Sept 2026 PMID 42692024
  6. Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma. Cell reports. Medicine · 25 Aug 2026 PMID 42641597
  7. Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study). Oral oncology · 18 Aug 2026 PMID 42612404
  8. The LncRNA-Tumor Immune Microenvironment Nexus: Integrative Insights for Cancer Immunotherapy. Genomics, proteomics & bioinformatics · 18 Aug 2026 PMID 42608821
  9. pH-Responsive liposomes co-delivering a membrane-active peptide and the PI3Kγ inhibitor to reconstruct the tumor microenvironment for enhanced antitumor immunotherapy. Biomaterials science · 17 Aug 2026 PMID 42605855
  10. Your neighbors matter: Adjacent cancer cells dampen TLS function. Cancer cell · 9 Jul 2026 PMID 42425073
Mechanisms of Checkpoint Response (9)
  1. Diet-microbiome interactions enhance cancer immunotherapy in obesity. Cell metabolism · 6 Oct 2026 PMID 42838033
  2. Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia. Cancer discovery · 15 Sept 2026 PMID 42742315
  3. Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
  4. Metabolic predictors of response to immunotherapy in locally advanced or metastatic esophageal cancer: unveiling the obesity paradox. Scientific reports · 8 Sept 2026 PMID 42711346
  5. Low-Density Lipoprotein-Mimetic Nanoparticles Codelivering Self-Activated Cabazitaxel Prodrug and Verteporfin for Tumor Chemophotodynamic Therapy and Immune Activation. Molecular pharmaceutics · 7 Sept 2026 PMID 42704120
  6. LIM and SH3 protein 1 deficiency confers resistance to cytotoxic lymphocyte-mediated lysis and immunotherapy in gastric cancer by disrupting cytoskeleton dynamics. Journal for immunotherapy of cancer · 2 Sept 2026 PMID 42686372
  7. Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses. Cell reports. Medicine · 12 Aug 2026 PMID 42586064
  8. Noninvasive deciphering of the immunosuppressive tumor microenvironment and evaluation of MerTK inhibitor mediated reversal of ICB resistance via MerTK-targeted PET. Bioorganic chemistry · 30 Jun 2026 PMID 42379015
  9. A Single-Cell Guided Machine Learning Model Predicts Response to Immune Checkpoint Inhibitors in Gastric Cancer. Journal of chemical information and modeling · 11 Jun 2026 PMID 42273856
Immunotherapy in Lung Cancer (7)
  1. The Relationship Between Hospital Immunotherapy Volume and Treatment and Survival of Advanced Cutaneous Melanoma. The Journal of surgical research · 2 Oct 2026 PMID 42826672
  2. Outcomes of long-term responders to immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). A retrospective regional study. Lung cancer (Amsterdam, Netherlands) · 23 Sept 2026 PMID 42777508
  3. Adjuvant immunotherapy in resectable non-small cell lung cancer with nodal downstaging. Lung cancer (Amsterdam, Netherlands) · 3 Sept 2026 PMID 42691831
  4. Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study. Lung cancer (Amsterdam, Netherlands) · 17 Aug 2026 PMID 42607379
  5. Targeting the METTL14/Wnt9a/β-catenin pathway with pharmacological inhibitors enhances radiotherapy and immunotherapy efficacy in non-small cell lung cancer. European journal of pharmacology · 6 Aug 2026 PMID 42562044
  6. Impact of immunotherapy on overall survival and healthcare costs in advanced/metastatic lung cancer: A real-world study in France. Lung cancer (Amsterdam, Netherlands) · 24 Jul 2026 PMID 42497525
  7. Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42440365
Others — Immunotherapy Response and Access (16)
  1. Comprehensive Immunoprofiling and Multi-Omics Modeling Reveal Key Immune Features Associated with Disease Progression and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma. Cancer letters · 11 Nov 2026 PMID 43014538
  2. Consistency between Motor Nerve Conduction Studies and Changes in Clinical variables: A CIDP cohort study. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 31 Oct 2026 PMID 42963463
  3. Identifying barriers to immunotherapy access for triple-negative breast cancer: A qualitative analysis of interviews with medical oncologists. PloS one · 26 Oct 2026 PMID 42932373
  4. Turning the tables: Repurposing neuroplasticity to defeat cancer. Science translational medicine · 7 Oct 2026 PMID 42842723
  5. CT radiomics showed no improvement beyond volume dynamics for early lesion-level size response to immunotherapy in metastatic melanoma. Cancer imaging : the official publication of the International Cancer Imaging Society · 2 Oct 2026 PMID 42823717
  6. Beyond tumor response: hope and decision regret during immunotherapy for hepatocellular carcinoma. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 20 Sept 2026 PMID 42763822
  7. Integrated molecular and immune profiling identifies FOXA1 as a complementary co-target to MUC1 for bispecific immunotherapy in breast cancer. Functional & integrative genomics · 11 Sept 2026 PMID 42726297
  8. Clinical translation of senescence-related pan-cancer multi-omics: tools for assessment and immunotherapy prediction. Cancer gene therapy · 10 Sept 2026 PMID 42722723
  9. Targeting of tripartite neuron-cancer-immune cell crosstalk augments response to chemotherapy and immunotherapy. Cell reports. Medicine · 18 Aug 2026 PMID 42612638
  10. Lineage-specific pulmonary transcriptome landscape of coronavirus infection unveils universal immunotherapy for viral pneumonia. Molecular therapy : the journal of the American Society of Gene Therapy · 11 Aug 2026 PMID 42576386
  11. TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future oncology (London, England) · 31 Jul 2026 PMID 42535874
  12. Q&A: Timothy Yap on Clinical Trials and Drug Development. Cancer discovery · 23 Jul 2026 PMID 42488995
  13. Identification of polyamine metabolism-related gene signatures for prognostic and immunological stratification in glioma. Neuroscience · 29 Jun 2026 PMID 42373010
  14. Immunotherapy decision coaching for people with multiple sclerosis - Implementation of an interprofessional decision support programme into clinical practice. Multiple sclerosis and related disorders · 11 Jun 2026 PMID 42276023
  15. Suspected autoimmune cerebellar ataxia: Predictors of immunotherapy response and diagnosis reclassification to neurodegenerative disease. Journal of the neurological sciences · 10 Jun 2026 PMID 42269360
  16. Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database. Current problems in cancer · 9 Jun 2026 PMID 42263372
Others — Antigen-Targeted Immune Therapies (4)
  1. A Non-autonomous Delayed Model for Combined Cancer Therapies with Experimental Parameter Estimation. Bulletin of mathematical biology · 11 Nov 2026 PMID 43015519
  2. A phase 1 feasibility trial of BE-CAR33, an "off-the-shelf" base-edited CAR33 T cell therapy for acute myeloid leukemia. Science translational medicine · 19 Aug 2026 PMID 42616838
  3. Preclinical evaluation of nitrated α-synuclein-specific CAR-Treg therapy in Parkinson's disease. Cell reports. Medicine · 12 Aug 2026 PMID 42586065
  4. Oral immunotherapy with anti-ES24 antibodies reduces burden and fecundity of Haemonchus contortus and inflammation in lambs artificially infected. Vaccine · 1 Aug 2026 PMID 42542049

By study type

Clinical trials (2)
  1. A phase 1 feasibility trial of BE-CAR33, an "off-the-shelf" base-edited CAR33 T cell therapy for acute myeloid leukemia. Science translational medicine · 19 Aug 2026 PMID 42616838
  2. TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future oncology (London, England) · 31 Jul 2026 PMID 42535874
Observational studies and case reports (11)
  1. Consistency between Motor Nerve Conduction Studies and Changes in Clinical variables: A CIDP cohort study. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 31 Oct 2026 PMID 42963463
  2. The Relationship Between Hospital Immunotherapy Volume and Treatment and Survival of Advanced Cutaneous Melanoma. The Journal of surgical research · 2 Oct 2026 PMID 42826672
  3. CT radiomics showed no improvement beyond volume dynamics for early lesion-level size response to immunotherapy in metastatic melanoma. Cancer imaging : the official publication of the International Cancer Imaging Society · 2 Oct 2026 PMID 42823717
  4. Outcomes of long-term responders to immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). A retrospective regional study. Lung cancer (Amsterdam, Netherlands) · 23 Sept 2026 PMID 42777508
  5. Beyond tumor response: hope and decision regret during immunotherapy for hepatocellular carcinoma. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 20 Sept 2026 PMID 42763822
  6. Adjuvant immunotherapy in resectable non-small cell lung cancer with nodal downstaging. Lung cancer (Amsterdam, Netherlands) · 3 Sept 2026 PMID 42691831
  7. Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study). Oral oncology · 18 Aug 2026 PMID 42612404
  8. Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study. Lung cancer (Amsterdam, Netherlands) · 17 Aug 2026 PMID 42607379
  9. Impact of immunotherapy on overall survival and healthcare costs in advanced/metastatic lung cancer: A real-world study in France. Lung cancer (Amsterdam, Netherlands) · 24 Jul 2026 PMID 42497525
  10. Suspected autoimmune cerebellar ataxia: Predictors of immunotherapy response and diagnosis reclassification to neurodegenerative disease. Journal of the neurological sciences · 10 Jun 2026 PMID 42269360
  11. Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database. Current problems in cancer · 9 Jun 2026 PMID 42263372
Human data, design not indexed (7)
  1. Identifying barriers to immunotherapy access for triple-negative breast cancer: A qualitative analysis of interviews with medical oncologists. PloS one · 26 Oct 2026 PMID 42932373
  2. Integrated molecular and immune profiling identifies FOXA1 as a complementary co-target to MUC1 for bispecific immunotherapy in breast cancer. Functional & integrative genomics · 11 Sept 2026 PMID 42726297
  3. Metabolic predictors of response to immunotherapy in locally advanced or metastatic esophageal cancer: unveiling the obesity paradox. Scientific reports · 8 Sept 2026 PMID 42711346
  4. Q&A: Timothy Yap on Clinical Trials and Drug Development. Cancer discovery · 23 Jul 2026 PMID 42488995
  5. Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42440365
  6. Identification of polyamine metabolism-related gene signatures for prognostic and immunological stratification in glioma. Neuroscience · 29 Jun 2026 PMID 42373010
  7. Immunotherapy decision coaching for people with multiple sclerosis - Implementation of an interprofessional decision support programme into clinical practice. Multiple sclerosis and related disorders · 11 Jun 2026 PMID 42276023
Preclinical: animal, cell and lab studies (22)
  1. A Non-autonomous Delayed Model for Combined Cancer Therapies with Experimental Parameter Estimation. Bulletin of mathematical biology · 11 Nov 2026 PMID 43015519
  2. Engineering Subcutaneous Ectopic Tertiary Lymphoid Structures as Personalized Immune-Activation Niches for Cancer Immunotherapy. ACS applied bio materials · 20 Oct 2026 PMID 42900868
  3. Turning the tables: Repurposing neuroplasticity to defeat cancer. Science translational medicine · 7 Oct 2026 PMID 42842723
  4. Diet-microbiome interactions enhance cancer immunotherapy in obesity. Cell metabolism · 6 Oct 2026 PMID 42838033
  5. Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science translational medicine · 16 Sept 2026 PMID 42748218
  6. Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
  7. Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
  8. Decondensing cancer immunotherapy. Science (New York, N.Y.) · 10 Sept 2026 PMID 42721256
  9. Low-Density Lipoprotein-Mimetic Nanoparticles Codelivering Self-Activated Cabazitaxel Prodrug and Verteporfin for Tumor Chemophotodynamic Therapy and Immune Activation. Molecular pharmaceutics · 7 Sept 2026 PMID 42704120
  10. Surface display of co-stimulatory ligand B7H2 on engineered bacteria enhances tumor immunotherapy. Cell reports. Medicine · 3 Sept 2026 PMID 42692024
  11. LIM and SH3 protein 1 deficiency confers resistance to cytotoxic lymphocyte-mediated lysis and immunotherapy in gastric cancer by disrupting cytoskeleton dynamics. Journal for immunotherapy of cancer · 2 Sept 2026 PMID 42686372
  12. Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma. Cell reports. Medicine · 25 Aug 2026 PMID 42641597
  13. Targeting of tripartite neuron-cancer-immune cell crosstalk augments response to chemotherapy and immunotherapy. Cell reports. Medicine · 18 Aug 2026 PMID 42612638
  14. pH-Responsive liposomes co-delivering a membrane-active peptide and the PI3Kγ inhibitor to reconstruct the tumor microenvironment for enhanced antitumor immunotherapy. Biomaterials science · 17 Aug 2026 PMID 42605855
  15. Preclinical evaluation of nitrated α-synuclein-specific CAR-Treg therapy in Parkinson's disease. Cell reports. Medicine · 12 Aug 2026 PMID 42586065
  16. Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses. Cell reports. Medicine · 12 Aug 2026 PMID 42586064
  17. Lineage-specific pulmonary transcriptome landscape of coronavirus infection unveils universal immunotherapy for viral pneumonia. Molecular therapy : the journal of the American Society of Gene Therapy · 11 Aug 2026 PMID 42576386
  18. Targeting the METTL14/Wnt9a/β-catenin pathway with pharmacological inhibitors enhances radiotherapy and immunotherapy efficacy in non-small cell lung cancer. European journal of pharmacology · 6 Aug 2026 PMID 42562044
  19. Oral immunotherapy with anti-ES24 antibodies reduces burden and fecundity of Haemonchus contortus and inflammation in lambs artificially infected. Vaccine · 1 Aug 2026 PMID 42542049
  20. Your neighbors matter: Adjacent cancer cells dampen TLS function. Cancer cell · 9 Jul 2026 PMID 42425073
  21. Noninvasive deciphering of the immunosuppressive tumor microenvironment and evaluation of MerTK inhibitor mediated reversal of ICB resistance via MerTK-targeted PET. Bioorganic chemistry · 30 Jun 2026 PMID 42379015
  22. A Single-Cell Guided Machine Learning Model Predicts Response to Immune Checkpoint Inhibitors in Gastric Cancer. Journal of chemical information and modeling · 11 Jun 2026 PMID 42273856
Unclassified: not yet indexed with MeSH (4)
  1. Comprehensive Immunoprofiling and Multi-Omics Modeling Reveal Key Immune Features Associated with Disease Progression and Clinical Outcomes in Patients with Unresectable Hepatocellular Carcinoma. Cancer letters · 11 Nov 2026 PMID 43014538
  2. Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia. Cancer discovery · 15 Sept 2026 PMID 42742315
  3. Clinical translation of senescence-related pan-cancer multi-omics: tools for assessment and immunotherapy prediction. Cancer gene therapy · 10 Sept 2026 PMID 42722723
  4. The LncRNA-Tumor Immune Microenvironment Nexus: Integrative Insights for Cancer Immunotherapy. Genomics, proteomics & bioinformatics · 18 Aug 2026 PMID 42608821